Good Harbor Advisors’s AbbVie ABBV Stock Holding History

Good Harbor Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$749K	Buy	2,976 +4	+0.1%	+$861	0.73%	31
2026 Q1	$646K	Buy	2,972 +1	+0%	+$222	0.71%	36
2025 Q4	$679K	Buy	+2,971	New	+$677K	0.79%	29

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Good Harbor Advisors's ABBV Position: Q2 2026 in Review

Good Harbor Advisors increased its AbbVie (ABBV) stake by 0.13% in Q2 2026, buying an estimated $861 and bringing the position to 2,976 shares worth $749K. The position accounts for 0.73% of the portfolio, ranked #31.

Good Harbor Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Good Harbor Advisors held 2,976 shares of AbbVie worth $749K as of Q2 2026.
Good Harbor Advisors bought 4 AbbVie shares in Q2 2026, an estimated $861.
AbbVie made up 0.73% of Good Harbor Advisors's portfolio in Q2 2026, its #31 holding.
Good Harbor Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Good Harbor Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.